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Abstract
Background: We examined colorectal, breast, and prostate cancer screening utilization in eligible populations
within three data cross-sections, and identified factors potentially modifying cancer screening utilization in Swiss
adults.
Methods: The study is based on health insurance claims data of the Helsana Group. The Helsana Group is one of
the largest health insurers in Switzerland, insuring approximately 15% of the entire Swiss population across all
regions and age groups. We assessed proportions of the eligible populations receiving colonoscopy/fecal occult
blood testing (FOBT), mammography, or prostate-specific antigen (PSA) testing in the years 2014, 2016, and 2018,
and calculated average marginal effects of individual, temporal, regional, insurance-, supply-, and system-related
variables on testing utilization using logistic regression.
Results: Overall, 8.3% of the eligible population received colonoscopy/FOBT in 2014, 8.9% in 2016, and 9.2% in
2018. In these years, 20.9, 21.2, and 20.4% of the eligible female population received mammography, and 30.5, 31.1,
and 31.8% of the eligible male population had PSA testing. Adjusted testing utilization varied little between 2014
and 2018; there was an increasing trend of 0.8% (0.6–1.0%) for colonoscopy/FOBT and of 0.5% (0.2–0.8%) for PSA
testing, while mammography use decreased by 1.5% (1.2–1.7%). Generally, testing utilization was higher in French-
speaking and Italian-speaking compared to German-speaking region for all screening types. Cantonal programs for
breast cancer screening were associated with an increase of 7.1% in mammography utilization. In contrast, a high
density of relevant specialist physicians showed null or even negative associations with screening utilization.
Conclusions: Variation in cancer screening utilization was modest over time, but considerable between regions.
Regional variation was highest for mammography use where recommendations are debated most controversially,
and the implementation of programs differed the most.
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Background
In Switzerland, cancer was the second most common
cause of death in 2017 [1]. Cancer was shown to have
overtaken cardiovascular diseases as the leading cause
of death in 12 European Union countries [2]. In
Switzerland as well as internationally, public health
officials and disease advocacy groups have worked
hard in the past years to persuade the population of
the importance of targeted cancer screening. These
efforts have led to an increased uptake of screening,
both in Switzerland and internationally, and have
yielded intended results. For example, screening col-
onoscopy was associated with decreased colorectal
cancer incidence and mortality [3, 4]. The proportion
of colorectal cancer deaths preventable by colonos-
copy use within 10 years has been estimated to be
30.7% in Germany, and 33.9% in the United States
[5]. However, while many guidelines consistently rec-
ommend the use of some preventive measures, such
as colorectal cancer screening in certain age groups
[6], other screenings, such as breast cancer screening,
continue to be controversial because it is unclear
whether lifetime benefits outweigh harms and costs in
individuals [7]. Many adults receive routine cancer
screening even in old age when it is no longer recom-
mended [8]. The burden associated with overdiagnosis
and overtreatment is becoming an increasingly recog-
nized issue.
In Switzerland, colorectal cancer screening is recom-
mended routinely between the age of 50 and 69 years,
while routine screening of prostate cancer is discouraged
without prior comprehensive education of the patient on
benefits and harms and shared decision-making [6, 9]. In
fact, prostate-specific antigen (PSA)-based screening
without prior informed decision making is one of five
listed procedures to be avoided in the ambulatory sector,
according to the Swiss Society of Internal Medicine
(www.smartermedicine.ch). Breast cancer screening is
often recommended, but this recommendation is de-
bated in Switzerland [7, 10]. Since 2011, an increasing
number of cantons established breast cancer screening
programs. Overall, the implementation of cancer screen-
ing programs differs considerably between cantons. Pre-
vious research, mainly based on the years 2007 to 2012,
has found substantial temporal and regional variation in
cancer screening utilization for all three cancer types in
Switzerland [11–13]. Thereby, screening rates were gen-
erally higher in urban areas and in French- and Italian-
speaking regions compared to German-speaking region
[11–13]. While breast cancer screening utilization de-
creased over time in Switzerland, as well as in Europe
and the US [13–15], colorectal cancer screening
utilization seemed to increase [12, 16]. Prostate cancer
screening utilization varied with increasing numbers in
Switzerland and Sweden and decreasing trends in the
US [11, 17, 18]. However, more recent findings are
lacking.
Besides system-related factors, like the existence of
national or cantonal screening programs, further factors
seem to play a role in whether or not persons participate
in cancer screening, such as individual and supply-
related variables [8, 19–22]. Furthermore, the patient’s
type of health insurance plan and healthcare utilization
(such as physician consultations) were associated with
cancer screening utilization [23, 24]. Knowledge in the
field of cancer screening coverage and its related factors
is important for healthcare providers and policymakers
as well as for patients when debating on the future
directions of planning and resource allocation. Real-
world and updated data obtained from routinely col-
lected sources such as health insurance claims are par-
ticularly suitable for the study of screening coverage,
because they are not collected by means of self-reporting
and, as such, results are not distorted due to inherent re-
call bias [25]. We therefore aimed to examine colorectal,
breast, and prostate cancer screening utilization in the
appropriate target populations in the years 2014, 2016,
and 2018. Moreover, we aimed to identify factors poten-
tially modifying cancer screening utilization in Swiss
adults, based on health insurance claims data.
Materials and methods
Study design and study population
This is a retrospective, observational study based on
insurance claims data of adults, who were insured at
Helsana Group in the period from January to December
of the years 2014, and/or 2016, and/or 2018, and also in
the year preceding each applicable cross-section. The
Helsana Group is one of the largest health insurers in
Switzerland, insuring approximately 15% of the entire
Swiss population across all regions and age groups.
Health insurance is mandatory for all Swiss citizens and
is based on a cost sharing obligatory basic coverage con-
sisting of deductibles and co-payments. The height of
the deductible ranges from Swiss Francs (CHF) 300 to
2500 and can - to some extent - be chosen by the
insured person, whereby higher deductibles lead to lower
premiums. Co-payments amount to 10% of the yearly
healthcare costs and are limited to CHF 700 per person
per year. On top of the mandatory insurance, citizens
can buy supplementary hospital insurance, which covers
further comfort of (semi-)private wards, free choice of
physician, and speed of access to elective procedures.
In Switzerland, colorectal cancer screening is recom-
mended routinely between the age of 50 and 69 years,
using fecal occult blood testing (FOBT) biennially or col-
onoscopy every 10 years [6]. These opportunistic screen-
ings are reimbursed by mandatory health insurance
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since 2013 but are not exempted from deductible. Can-
tonal screening programs exist since January 1st, 2015 in
the canton of Uri, and since September 1st, 2015 in the
canton of Vaud. Screenings at the ages 50 to 69 years
within these cantonal programs are exempted from
deductible, but participants still owe a 10% co-payment.
Further cantonal programs did not start before 2019. So,
in the years 2016 and 2018, 90.4 and 90.5% of the Swiss
population lived in a canton without a colorectal cancer
screening program. Between the age of 50 and 69 years
(or 74, depending on the canton), mammography is
recommended for breast cancer screening biennially
[26]. Opportunistic screenings are reimbursed by
mandatory health insurance, but they lack quality con-
trol of mammography and are not systematically moni-
tored [10]. All mammography screenings in the context
of breast cancer screening programs (programmatic
screenings) in the cantons of Thurgau, Neuchâtel,
Fribourg, Jura, Geneva, Bern, Valais, Vaud (for women
between ages 50–74 years), as well as in the cantons of
Grisons and St. Gallen (for women between ages 50–69
years) are exempted from deductible, but participants
still owe 10% co-payment, except for Jura (up to Decem-
ber 31st 2017) and Valais (up to December 31st 2016),
where co-payments are covered by a foundation. In mid-
2014, a cantonal screening program was introduced in
Basel, and beginning 2015, a further program started in
the canton of Ticino (for women aged 50–69 years).
Taken together, in the years 2014, 2016, and 2018, 50.6,
40.8 and 41.0% of the Swiss population lived in a canton
without a breast cancer screening program. Finally, rou-
tine screening of prostate cancer is discouraged by
guidelines [9]. No national or cantonal screening pro-
gram exists.
For each of the observed years, men or women aged
50 to 74 years were considered eligible for prostate or
breast cancer screening, respectively, while individuals
aged 50 to 69 years were considered eligible for colorec-
tal cancer screening. Collectively across all three data
cross-sections, 10.3% individuals of the colorectal, 8.0%
of the breast, and 6.3% of the prostate cancer screening
populations with missing data (enrollees without full
coverage during the observation time, enrollees living
abroad, Helsana employees, and enrollees seeking asy-
lum) were excluded. Consequently, the final study popu-
lation for colorectal cancer screening comprised 270′
576, 261′682, and 244′328 individuals in the year 2014,
2016, and 2018, respectively. The corresponding num-
bers were 171′186, 166′675, and 165′328 for breast, as
well as 160′661, 157′269, and 155′944 for prostate can-
cer screening.
The present study falls outside the scope of the
Swiss Federal Act on Research involving Human
Beings (Human Research Act, HRA), because it is
retrospective and based on anonymized routine
administrative claims data. No informed consent from
patients or further ethics approval was needed, as all
requirements of article 22 of the Swiss data protection law
were fulfilled. This was confirmed by a waiver of the ethics
committee (Kantonale Ethikkommission Zürich, dated
January 11, 2017).
Measures
Inpatient and outpatient codes used to identify screening
services have been published elsewhere [27]. In short,
colonoscopy, mammography and PSA testing were used
to define colorectal, breast or prostate cancer screening
utilization, regardless of whether the tests were used for
screening or diagnostic purposes. In contrast to Ulyte
et al., we additionally considered FOBT as a colorectal
cancer screening test. Sociodemographic factors (sex and
age), health-related factors (number of chronic condi-
tions assessed by means of the Pharmacy-based Cost
Group (PCG) model [28], and having had a major sur-
gery or disease associated with the specific cancer of
interest, based on inpatient and outpatient diagnoses
and treatments in the preceding year (specific disease)),
as well as the patient’s type of health insurance plan
(supplementary hospital insurance, managed care, and
deductible level) were included as explanatory variables.
Regional (urban/ rural residence and language region
(German, French or Italian)) and system-related factors
(existence of a cantonal screening program) were also
considered. In the present data set, adults from two can-
tons belonging to two different language regions were
enrolled; the canton of Bern (BE) incorporates German-
speaking and French-speaking regions, and the canton
of Grisons (GR) incorporates German-speaking and
Italian-speaking regions. The Rhaeto-Romanic region of
GR (hosting < 1% of inhabitants) was assigned to the
German-speaking region. Furthermore, screening spe-
cific specialist physician density information of the cor-
responding year was provided by the Swiss Medical
Association (FMH) and included as supply-related factor
(gastroenterologist in colonoscopy/FOBT, gynecologist
in mammography, and urologist in PSA testing
utilization). Finally, beyond the respective screening
(specific testing), the following healthcare utilization
measures were considered as explanatory variables: the
number of physician consultations, total healthcare
costs, and at least one acute hospital admission, all mea-
sured in the preceding year, as well as colonoscopy/
FOBT in the same year (for mammography and PSA
testing analysis).
Most variables were originally measured on a nominal
scale. All continuously measured variables were trans-
formed into categories before their use in regression
analysis (age (five-year groups), height of deductible
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(above CHF 500 yes/no), specialist physician density
(above median density yes/no), number of chronic con-
ditions (none, one, multiple), number of physician con-
sultations (quarters), healthcare costs (quarters), and
acute hospital admissions (at least one yes/no).
Statistical analysis
The baseline characteristics of all included study sub-
jects are presented as counts and percentages, or as
mean and standard deviation for continuous variables.
For each of the three screening types, we compared
subjects with and without the respective testing. We
calculated the testing prevalence per year (2014, 2016,
2018) for each cancer screening type, and we then
tested whether the testing prevalences were equal
using Chi-squared tests, pairwise between years (with
Holm correction for multiple testing), as well as
across all 3 years. Additionally, we calculated the age-
standardized testing prevalence per canton. Small can-
tons with low numbers of observations were grouped
with a neighboring canton where sensible (Appenzell
Innerrhoden and Appenzell Ausserrhoden, Neuchâtel
and Jura, Obwalden and Nidwalden for colorectal
cancer screening, and Uri and Glarus for breast and
prostate cancer screening). Furthermore, a simple
probability-rate-probability conversion (assuming con-
stant testing rates) was performed to estimate the
longer-term testing prevalence, thereby taking the rec-
ommended screening interval into account [29].
In logistic regression models with testing in a given
year as outcome variable, we calculated the average mar-
ginal effect, i.e. the averaged difference in the predicted
probability of having the outcome, for each of the
included covariates [30, 31]. In conjunction with the fact
that all included covariates are categorical, the average
marginal effects facilitate the interpretation of each asso-
ciation (direction and magnitude) between each covari-
ate and the outcome on the probability scale. This
exploratory analysis was performed on the pooled data
of all three cross-sections, for each screening type separ-
ately. One assumption in logistic regression is the inde-
pendence of all observations, which is violated in the
pooled cross-sections where some subjects are observed
in more than one cross-section. This violation could
have led to a wrong estimation of the variance in the
effect estimates. A sensitivity analysis using clustered
covariance matrix estimation with individuals as clusters
showed similar interval estimates for most covariates
[32–34]. Since we have very few (one to three) observa-
tions per cluster, these estimations may not work well,
and we therefore show these results as supplementary
material only (Additional file 3) [34].
All analyses were performed using R version 3.6.1.
Results
Overall, the mean (sd) age was 59.1 (5.95) years, 61.7 (7.37)
years, and 61.6 (7.58) years, respectively, in the colorectal,
breast and prostate cancer screening populations. Men were
slightly under-represented in the colorectal cancer screening
population (48.3%). Characteristics of the populations for the
year 2018 are shown in Table 1, and corresponding charac-
teristics for the years 2014 and 2016 are available as supple-
mentary material (Additional files 1 and 2).
Overall, 8.3% of the eligible population received colon-
oscopy/FOBT in 2014, 8.9% in 2016, and 9.2% in 2018.
This corresponds to a small, but statistically significant
increase between 2014 and 2018 (Table 2). While the
proportion of persons with FOBT decreased (from 2.5%
in 2014 to 2.1% in 2018), the number of persons with
colonoscopy slightly increased (from 6.1% in 2014 to
7.4% in 2018). Regarding breast cancer screening, 20.9,
21.2, and 20.4% of the eligible population had mammog-
raphy in 2014, 2016, and 2018, respectively. The corre-
sponding numbers of PSA testing in the eligible prostate
cancer screening population were 30.5, 31.1, and 31.8%.
Assuming constant utilization rates, approximately 58%
of eligible persons were estimated to have had colorectal
cancer screening (54% with colonoscopy within 10 years,
and 4% with FOBT within 2 years), and about 37% to
have had breast cancer screening (mammography within
2 years) by 2018.
Looking at the adjusted testing utilization in multivari-
able regression analysis, there was a slight increase in
colonoscopy/FOBT utilization of 0.6% (CI: 0.4–0.7%) in
2016 and 0.8% (CI: 0.6–1.0%) in 2018 as compared to
2014 (Fig. 1). These adjusted increases correspond to the
raw increases of 0.6% between 2014 and 2016, and of
0.8% between 2014 and 2018 (Table 2). Mammography
utilization slightly decreased by 0.6% (CI: 0.3–0.8%) in
2016 and by 1.5% (CI: 1.2–1.7%) in 2018, compared to
2014. This is contradictory to the minimal increase of
0.3% between 2014 and 2016, but similar to the slight
decrease of 0.5% between 2014 and 2018, when looking
at the raw proportions. The utilization of PSA testing
remained unchanged in 2016 and increased slightly in
2018 (by 0.5%; CI 0.2–0.8%) compared to 2014. These
slightly attenuated results are comparable to the changes
in raw proportions.
In multivariable regression analysis, several determi-
nants were associated with testing utilization (Fig. 1 and
Additional file 3). Utilization increased with increasing
age for colonoscopy/FOBT and even more strongly for
PSA testing but decreased slightly with increasing age
for mammography use. Being female was associated with
a 1% (CI: 0.9–1.1%) lower probability of receiving colon-
oscopy/FOBT. Having had a major surgery or disease as-
sociated with the specific cancer of interest was strongly
related to receiving colonoscopy/FOBT, mammography,
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or PSA testing in the observed year, although this
applied to a small proportion of patients. Having one or
more chronic conditions was positively associated with
colonoscopy/FOBT and PSA testing, whereas multiple
chronic conditions were slightly negatively associated
with mammography use. Regarding the patient’s type of
health insurance plan, having supplementary hospital in-
surance was consistently associated with a 1.9 to 4.8%
higher probability of testing utilization, depending on
cancer type, while having a higher deductible was con-
sistently associated with a 1.7 to 5.3% lower probability
of testing utilization. The positive effect of being in a
managed care model on testing utilization was minimal,
but slightly higher for mammography use than for
receiving colonoscopy/FOBT.
When compared to the German-speaking region,
living in the Italian-speaking region was associated with
a higher probability of receiving colonoscopy/FOBT,
whereas living in the French-speaking region had almost
no effect. In contrast, living in the French- and the
Italian- compared to the German-speaking region in-
creased mammography use by 13.0% (CI: 12.6–13.4%)
and 12.8% (CI: 12.3–13.3%), respectively, and PSA test-
ing by 6.5% (CI: 6.1–6.8%) and 9.6% (CI: 9.2–10.1%), re-
spectively. The average marginal effect of living in the
rural area on testing utilization was negative, but mostly
small, for all cancer types. The existence of a cantonal
program had a positive impact of 7.1% (CI: 6.8–7.4%) on
mammography utilization, as well as a small positive im-
pact of 0.9% (CI: 0.5–1.2%) on colonoscopy/FOBT
utilization. While the cantonal density of gastroenterolo-
gists and gynecologists seemed to have no influence on
colonoscopy/FOBT and mammography utilization, the
cantonal density of urologists was negatively associated
with PSA testing.
High healthcare utilization, assessed by higher healthcare
costs and more physician consultations in the preceding
year, were both associated with a higher probability of being
tested for all cancer types. Furthermore, receiving colonos-
copy/FOBT in the corresponding year was highly related to








N (%) 22′453 (9.2) 221′875 (90.8) 33′747 (20.4) 131′581 (79.6) 49′521 (31.8) 106′423 (68.2)
Male sex (%) 10′876 (48.4) 107′027 (48.2) 0 (0) 0 (0) 49′521 (100) 106′423 (100)
Age in years (mean, sd) 59.8 (5.94) 59.0 (5.90) 61.1 (7.17) 61.9 (7.43) 64.0 (7.36) 60.5 (7.48)
High deductible (%) 4′869 (21.7) 67′033 (30.2) 5′990 (17.7) 30′831 (23.4) 10′204 (20.6) 38′822 (36.5)
Managed care (%) 13′708 (61.1) 134′626 (60.7) 20′684 (61.3) 78′601 (59.7) 29′346 (59.3) 63′850 (60.0)
Suppl. hospital insurance (%) 5′620 (25.0) 48′174 (21.7) 9′795 (29.0) 33′285 (25.3) 12′909 (26.1) 20′838 (19.6)
Language region
German (%) 16′659 (74.2) 172′012 (77.5) 19′994 (59.2) 106′389 (80.9) 35′531 (71.7) 85′961 (80.8)
French (%) 3′629 (16.2) 34′750 (15.7) 9′297 (27.5) 17′196 (13.1) 8′724 (17.6) 14′485 (13.6)
Italian (%) 2′165 (9.6) 15′113 (6.8) 4′456 (13.2) 7′996 (6.1) 5′266 (10.6) 5′977 (5.6)
Urban region (%) 17′527 (78.1) 169′001 (76.2) 26′611 (78.9) 101′054 (76.8) 38′503 (77.8) 79′373 (74.6)
Major related surgery/ disease (%) 269 (1.2) 696 (0.3) 2′022 (6.0) 1′164 (0.9) 2′398 (4.8) 1′011 (0.9)
Chronic conditions (mean, sd) 1.8 (1.87) 1.4 (1.70) 1.8 (1.87) 1.6 (1.85) 2.0 (1.79) 1.3 (1.66)
Cantonal program (%) 1′359 (6.1) 12′526 (5.6) 21′654 (64.2) 61′795 (47.0) 0 (0) 0 (0)
a
FOBT Fecal occult blood testing
b
PSA Prostate-specific antigen
Table 2 Proportions of the eligible populations with colonoscopy/FOBT, mammography or PSA testing in 2014, 2016, and 2018, and
significance tests of change of these proportions, pairwise between years
2014 2016 2018 Change in proportion 20,
142,016
p
a Change in proportion
2016–2018
p






8.3% 8.9% 9.2% 0.7% <
0.001
0.2% 0.003 0.9% <
0.001








a using Chi-squared tests
b
FOBT Fecal occult blood testing
c
PSA Prostate-specific antigen
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mammography use and PSA testing in the observed year.
In contrast, the respective testing in the previous year
showed varying associations: Colonoscopy/FOBT in the
previous year was associated with a slightly higher probabil-
ity of receiving colonoscopy/FOBT in the observed year.
Previous PSA testing was strongly associated with re-
testing in the observed year, while mammography in the
previous year was negatively associated with present mam-
mography utilization. All the above-mentioned observed ef-
fects hardly changed when different observations periods
were analyzed separately (results not shown).
Looking at the regional distribution of age-
standardized testing utilization, we found significant dif-
ferences between the three language regions on the one
hand, and between cantons with and without screening
programs on the other hand. Since these interactions
cannot be captured by adjusted regression modelling, we
illustrate this interrelation in Fig. 2.
In bilingual cantons incorporating more than one lan-
guage region (BE, GR), both, the existence of a program
and the language region seem to influence screening
participation. In the German-speaking regions, the age-
standardized mammography utilization rates were
approximately 7% higher in cantons with a breast cancer
screening program compared to cantons without such a
program. Noteworthy, in 2018 in the German-speaking
part of Bern, where screening programs were reorga-
nized in 2017/2018, the utilization rate was significantly
lower than in the French-speaking part of Bern, where a
screening program was jointly established together with
the cantons of Jura and Neuchâtel in 2011. As all
French-speaking regions belonged to cantons with exist-
ing screening programs, the effect of a program in these
regions could not be evaluated. In the Italian-speaking
region (mainly represented by the canton of Ticino), the
utilization rate increased significantly after the introduc-
tion of the cantonal screening program in 2015. In con-
trast, this increase was much smaller in the canton of
Grisons, where only a small part of the population lives
in an Italian-speaking region. The supplement shows
corresponding bubble plots for colonoscopy/FOBT use
and PSA testing (Additional files 4 and 5).
Fig. 1 Standard estimates of the average marginal effects on colonoscopy/FOBT, mammography and PSA testing utilization. FOBT = fecal occult
blood testing; PCG = Pharmacy-based Cost Group
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Discussion
Variations in cancer screening utilization were modest
over time, but considerable between regions. Regional
variation was highest for mammography use where
recommendations are debated most intensively, and
the implementation of programs differed considerably.
The present study showed an increasing trend of 0.8%
(0.6–1.0%) for colonoscopy/FOBT and of 0.5% (0.2–
0.8%) for PSA testing, while mammography decreased
by 1.5% (1.2–1.7%) between 2014 and 2018.
Although colorectal cancer screening by means of col-
onoscopy or FOBT is clearly recommended and has been
promoted since 2014 in Switzerland, e.g. by pharmacies,
colonoscopy/FOBT utilization in this population-based
study was rather low and has hardly changed since then.
Considering the recommended ten-year screening interval
for colonoscopy and the two-year interval for FOBT,
about 58% of the eligible population would have been
tested by 2018. This proportion is slightly higher com-
pared to previous Swiss and Italian findings, but slightly
lower to screening participation in the US. In a Swiss
cross-sectional study conducted in 2017 [35], 41% of
patients who visited a primary care physician had a colon-
oscopy within 10 years and 4% had a FOBT within 2 years.
According to an earlier population-based Swiss survey in
50 to 75 year old persons, colorectal cancer screening de-
fined as endoscopy (either colonoscopy or sigmoidoscopy)
in the past 10 years or FOBT in the past 2 years increased
from 18.9% in 2007 to 22.2% in 2012; this increase within
5 years was more substantial compared to what we found,
and was due to growing endoscopy numbers in 2012,
while FOBT decreased [12]. The overall higher screening
utilization in our study might be owed to the addition of
colorectal cancer screening to the benefit basket of the
basic insurance coverage in Switzerland in 2013. More-
over, our inability to discriminate between diagnostic and
screening colonoscopy/FOBT, and the differences in study
designs (claims-based versus survey-based) might partially
explain the different findings. A recent Italian study in
women aged 50–54 years found participation rates within
the last 2 years for colorectal cancer screening (FOBT) of
45.1% [36]. In the US, 64.5% of respondents aged 50 to 75
years reported having participated in colorectal cancer
screening by 2010: [37].
Fig. 2 Age-standardized proportions of mammography utilization per canton, by language region and cantonal screening program. BE = canton
of Bern; GR = canton of Grisons. The columns illustrate different temporal cross-sections and the rows show different dominant languages in
cantons. Cantons in each row are further stratified by the existence of cantonal programs. BE and GR, which are bilingual cantons, are shown in
both linguistic rows. The size of the bubbles corresponds to the population size of the canton
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The slight decline in mammography utilization in our
study was similar to previous Swiss and European find-
ings. For example, the proportion of Swiss women with
any mammography in the last 12 months decreased from
19.1% in 2007 to 11.7% in 2012 in a survey data-based
study [13]. Annual participation rates for breast cancer
screening varied between 23 and 84% in 17 European
countries with mostly organized national or regional
breast screening programs, with a decreasing trend even
before 2014 [14]. Thus, mammography use within 1 year
of approximately 20% (or 37% within 2 years) presented
in our study is low when compared internationally. In a
recent Italian study, mammography use within 2 years
amounted to 85.1% [36]. Moreover, mammography use
increased from 48% in 2007/08 to 54% in 2011/12 in a
German city after the implementation of a mammog-
raphy screening program by the end of 2005 [38]. The
decline found in our analysis is likely to be influenced by
the public debate about benefits and harms of breast
cancer screening [39]. By the end of 2013, the Swiss
Medical Board recommended that no new systematic
mammography screening programs be introduced in
Switzerland due to lack of cost-effectiveness and un-
desirable effects outweighing desirable effects [40, 41].
The relative risk reduction or lifesaving effect is small,
while false-positive results and overdiagnosis can cause
considerable harm in screened patients [42, 43]. There-
fore, a more personalized approach is now recom-
mended in the US, meaning that physicians should have
a more informed discussion with patients.
Our analysis showed that proportions of PSA testing
remained above 30% between 2014 and 2018. These
rates seem rather high, given the uncertainty of the use-
fulness of PSA screening and the potential harm caused
by overdiagnosis and by associated overtreatment. This
is the reason why most organizations and Societies in
Europe and America, as well as the Swiss Medical Board,
recommend against routine PSA screening without prior
shared decision making [9, 44]. According to our find-
ings, the impact of the top five list by the Smarter Medi-
cine Initiatives (www.smartermedicine.ch), published in
2014, does not seem to have considerably impacted PSA
testing rates. Our results are in line with former Swiss
findings. Between 1992 and 2012, use of PSA screening
within the last 2 years increased from 32.6 to 42.4% in
Swiss men aged 50 years and older [11]. In contrast, a
US study demonstrated a decline in PSA testing after
the publication of the 2012 USPSTF recommendation
discouraging testing in asymptomatic men [44]. Since
PSA testing in our study is strongly associated with fur-
ther measures of healthcare utilization like the number
of consultations in the preceding year and concurrent
colonoscopy/FOBT use, and is mainly related to patients
with low deductibles and with multiple chronic
conditions, we might speculate that this specific testing
is done additionally in the course of other medical
examinations as no special equipment is needed.
In general, recommended screenings like colorectal
cancer screening have not clearly increased and discour-
aged screenings like prostate cancer screening have not
clearly decreased over time. However, the present results
need to be interpreted with caution, as we were unable
to discriminate between screening and diagnostic or
follow-up testing (except if screening occurred within a
cantonal program and was reimbursed as such). Particu-
larly in patients with a major related surgery or disease,
the colonoscopy/FOBT, mammography or PSA testing
might be attributable to diagnostic or follow-up testing
rather than screening purposes. This holds especially
true for colonoscopy which is only recommended once
in 10 years. However, the number of patients with
related disease or surgery is low.
Screening utilization was associated with a variety of
individual, regional, insurance-related, as well as with
supply-, and system-related factors. The direction of the
average marginal effects on testing utilization are com-
parable across all cancer types for most of these factors.
However, age was positively associated with colonos-
copy/FOBT and PSA testing, but inversely associated
with mammography. The decline in the latter in older
age is mostly owed to a lower probability in women aged
over 70 years where screening is no longer supported by
all cantonal programs. Being male was associated with a
higher prevalence of colonoscopy/FOBT use, similar to a
former Swiss study conducted in 2012 [12], but contrary
to a Flemish study, where utilization rates in 2013 and
2014 were lower for men [45].
Having supplementary hospital insurance was consist-
ently associated with a higher, while having a higher
deductible with a lower probability of screening
utilization. Similar findings were found for colorectal
[46], as well as for breast cancer screening [13, 47]. The
marginal positive effect of being in a managed care
model on cancer screening utilization is in line with a
previous study showing positive associations, where
slightly higher effects were observed for breast than for
colorectal cancer screening as well [24]. Though, the
effects observed in our study are small.
Screening utilization was generally more likely in the
French- and Italian-speaking regions compared to the
German-speaking region, except for colonoscopy/FOBT
use, where living in the French-speaking region hardly
had any effect. Regional variation was highest for mam-
mography use, where recommendations are debated
most and the implementation of programs differed con-
siderably. Correspondingly to our findings, significant
differences in breast cancer screening attendance be-
tween women in the French- and the German-speaking
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region were found in the study by Eichholzer et al. [48]
and Fenner et al. [13] Alike, prostate cancer screening
rates were higher in men living in the French- or Italian-
as compared to the German-speaking region, and in
urban rather than rural areas [11]. The proportions of
patients with either FOBT or colonoscopy also varied
widely between language regions [35] The increased
number of screening programs as well as the higher
screening utilization even in the absence of specific pro-
grams might point to a diverse attitude of patients and/
or physicians towards preventive measures in the
French- and Italian- compared to the German-speaking
region.
Cantonal programs for breast and colorectal cancer
screening were associated with a small, but significant
increase in testing utilization, although the association
was stronger in the former, since only two cantonal
colorectal cancer screening programs were in place by
2018, and because the overall proportion of persons re-
ceiving colonoscopy/FOBT was rather low. Generally,
despite an increasing number of cantons offering breast
cancer screening programs since 2011, the overall mar-
ginal effect showed a decreasing trend in mammography
utilization. This decline is mainly based on cantons with-
out any screening program. Similarly, the decline in
mammography screening was more pronounced in can-
tons with no or with a long-standing screening program
in the previous Swiss survey-based study [13]. In con-
trast, according to another Swiss study looking at data
from the Swiss Health Survey in the years 1997, 2002,
2007, and 2012, only a small part of the (relatively high)
mammography utilization rates could be attributed to
organized programs, and non-use of mammography was
not attributable to a lack of information or to financial
barriers [47]. Another Swiss study compared participants
of opportunistic with participants of organized mam-
mography screening and found that mammography
screening programs mainly attracted women in lower
socio-economic strata [49]. Unfortunately, we were un-
able to differentiate between those two screening types
by means of our data.
A high density of related specialist physicians had null
or even a negative association with screening utilization
in our study. This is in contrast to a German online sur-
vey where PSA testing was judged as useful by all urolo-
gists but only by half of the general practitioners, and
where PSA testing practices varied between both clin-
ician groups [50]. Higher PSA screening rates were also
seen in regions where the primary care specialist was
unlikely to be the predominant physician for ambulatory
visits [22]. We can only speculate that PSA testing is
done by primary care physicians to a very substantial
extent. At least, PSA testing was higher in those with
primary care physician visits in the preceding year [11].
High healthcare utilization, assessed by higher health-
care costs and more physician consultations in the pre-
ceding year, were both associated with a higher
probability of being tested for all three cancer types,
although this association was less strong in the highest
cost category. In line with our findings, having consulted
a primary care physician or a specialist physician in the
last 12 months was significantly associated with a higher
prevalence of colorectal cancer screening in Switzerland
in 2012 [12]. This implies that physicians assume their
obligation to talk with their patients about preventive
measures like cancer screening. Concurrent colonos-
copy/FOBT use increased the probability of mammog-
raphy or PSA testing. Likewise, US women who adhered
to breast cancer screening recommendations were four
times more likely to have had colorectal cancer screen-
ing [23]. PSA testing in the preceding year also increased
PSA testing in the observed year. This finding is congru-
ent to the clinical practice that individuals who are being
screened, are screened on a yearly basis. In contrast,
mammography in the preceding year was related to
lower mammography use in the observed year. This
might be indicative of the biennially screening recom-
mendations. Then again, colonoscopy/FOBT in the pre-
vious year hardly had any influence. As discussed
previously, the inability to discriminate between diagnos-
tic and screening testing on the one hand, and the differ-
ence in recommended screening intervals for
colonoscopy and FOBT on the other hand, might have
influenced these findings.
Strengths and limitations
Our study has several strengths and limitations worth men-
tioning. The major strength is the highly reliable and com-
prehensive, population-based data set available for analysis
over three cross-sections. The major limitation is that we
were unable to discriminate between screening and diagnos-
tic testing (except if screening occurred within a cantonal
program and was reimbursed as such). This misclassification
issue leads to an overestimation of screening utilization,
which might be more pronounced in breast and prostate
cancer screening where comparably more patients had
underlying diseases. In contrast, tests that have been paid
out-of-pocket were not captured by means of claims data,
which is more likely for PSA testing than for colonoscopy or
mammography. This may have led to an underestimation of
screening utilization. Furthermore, we might have missed
some codes used by specific laboratories to account for can-
cer screening. Second, observations were not necessarily in-
dependent between the different observation periods, which
may have led to an underestimation of the variance in the ef-
fect estimates. However, in a sensitivity analysis using
clustered covariance matrix estimation with individ-
uals as clusters, interval estimates altered only
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marginally (Additional file 3). Third, further aspects
influencing cancer screening participation in individ-
uals, like difference in life expectancy [51], screening
habits or patient’s preferences [23], could not be taken
into account by means of our claims data. Yet, we con-
sidered concurrent colonoscopy/FOBT use in the
breast and prostate cancer screening population as a
proxy for screening habit. Fourth, categorization of
continuous variables is sometimes discouraged, be-
cause it leads to information loss and assumes a flat
relationship between the covariate and the outcome
within intervals, which is less likely than e.g. a linear
relation in most cases [52]. While these reservations
are certainly true, we chose to categorize continuous
variables because in the case of this exploratory ana-
lysis the loss in precision is outweighed by the in-
creased interpretability of the results.
Implications
Clinical practice guidelines are an essential step forward to
improve patient care and provide recommendations based
on a systematic review of evidence [53]. However, although
clearly recommended, colorectal cancer screening is still
not performed by almost half of the eligible population.
Therefore, our findings highlight the need for enhanced
awareness of systematic colorectal cancer screening benefits
to reduce cancer-specific mortality rates. During a physician
consultation or hospitalization, strategies could be
employed to counsel, educate, and motivate patients to-
wards preventive measures like cancer screening, particu-
larly for those who are at higher risk of disease.
Furthermore, information campaigns and further actions
like invitation letters should more specifically address the
population who is less likely to be screened, e.g., individuals
with a high deductible. Offering of prevention and health
promotion to enrollees with supplementary health insur-
ance seem to go in that direction. Additionally, further can-
tonal programs were established in 2019 to hopefully
promote colorectal cancer screening. Yet, a standardization
of screening programs and their payments in Switzerland is
urgently warranted [54], and might help to increase equal
access and uptake.
Unnecessary screening may not only cause adverse ef-
fects but also generate high healthcare costs [55]. Re-
garding prostate cancer screening, annual PSA testing
may result in an overdiagnosis rate of 50% [56]. In-
creased awareness of initiatives such as the Smarter
Medicine recommendations of the Swiss Society of In-
ternal Medicine are therefore crucial. It should be noted
that screening attendance was shown to be mainly influ-
enced by social norms and role models [57], and not
solely by guidelines, even among physicians [53]. Thus,
physician training regarding informed decision making
as well as the development of improved information and
decision aids is warranted [11].
Although breast cancer screening is recommended
biennially, and various screening programs exist in
Switzerland, mammography use is low. Controversies
about the value of screening and further disparities, like
regional and system-related differences regarding pro-
gram implementation, might contribute to these find-
ings. For example, the risk of overdiagnosis and
overtreatment has been repeatedly demonstrated and
debated, particularly after breast cancer screening imple-
mentation [10, 43, 58, 59]. Further promoting interven-
tions for breast cancer screening, as mentioned in the
systematic review by Agide et al. [60], may therefore
have difficulties in being introduced in Switzerland.
However, unless screening participation reaches an ac-
ceptable standard level [14], it may not achieve the war-
ranted gains like a reduction in cancer-specific mortality.
Conclusions
Variations in cancer screening utilization were modest
over time, but considerable between regions. Regional
variations were highest for mammography use where
recommendations are debated most controversially.
Since recommended screening (like colorectal cancer
screening) has not clearly increased and discouraged
screening (like prostate cancer screening) has not clearly
decreased over time, health policy adoptions are needed
to optimize preventive care in Switzerland.
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